• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

当可能存在治疗与性别的交互作用时评估治疗方法。

Evaluating treatments when a gender by treatment interaction may exist.

作者信息

Russek-Cohen E, Simon R M

机构信息

Department of Animal Sciences, University of Maryland, College Park 20742, USA.

出版信息

Stat Med. 1997 Feb 28;16(4):455-64. doi: 10.1002/(sici)1097-0258(19970228)16:4<455::aid-sim382>3.0.co;2-y.

DOI:10.1002/(sici)1097-0258(19970228)16:4<455::aid-sim382>3.0.co;2-y
PMID:9044532
Abstract

We propose a two-stage procedure for investigating whether males and females respond differently to treatment. The size of the first stage is based on the assumption of homogeneity of treatment effects across genders. Using stage I, we test for a gender by treatment interaction. If non-significant, we compute an overall average treatment effect and terminate the study. If we find an apparent interaction at the end of the first stage, we consider each gender separately. Because we now need to estimate treatment effects separately for each gender, we may have a need to collect additional information in a second stage. We consider the performance of our procedure for a normally distributed endpoint as well as for a survival model.

摘要

我们提出了一个两阶段程序,用于研究男性和女性对治疗的反应是否不同。第一阶段的样本量基于治疗效果在不同性别间具有同质性的假设。在第一阶段,我们检验性别与治疗的交互作用。如果不显著,我们计算总体平均治疗效果并终止研究。如果在第一阶段结束时发现明显的交互作用,我们将分别考虑每个性别。由于我们现在需要分别估计每个性别的治疗效果,所以可能需要在第二阶段收集额外信息。我们考虑了该程序在正态分布终点以及生存模型方面的表现。

相似文献

1
Evaluating treatments when a gender by treatment interaction may exist.当可能存在治疗与性别的交互作用时评估治疗方法。
Stat Med. 1997 Feb 28;16(4):455-64. doi: 10.1002/(sici)1097-0258(19970228)16:4<455::aid-sim382>3.0.co;2-y.
2
On sample size calculation for 2x2 fixed-effect ANOVA when variances are unknown and possibly unequal.关于方差未知且可能不相等时2×2固定效应方差分析的样本量计算。
Br J Math Stat Psychol. 2009 May;62(Pt 2):417-25. doi: 10.1348/000711008X322853. Epub 2008 Jun 16.
3
Design and analysis of a 3-arm noninferiority trial with a prespecified margin for the hazard ratio.具有预先设定风险比界值的三臂非劣效性试验的设计与分析
Pharm Stat. 2018 Sep;17(5):489-503. doi: 10.1002/pst.1875. Epub 2018 Jul 9.
4
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?基于氟尿嘧啶的II期和III期结肠癌辅助治疗的汇总分析:哪些患者受益以及受益程度如何?
J Clin Oncol. 2004 May 15;22(10):1797-806. doi: 10.1200/JCO.2004.09.059. Epub 2004 Apr 5.
5
Analysis of time-to-event data under a two-stage survival adaptive design in clinical trials.临床试验中两阶段生存适应性设计下的事件发生时间数据分析。
J Biopharm Stat. 2010 Jul;20(4):705-19. doi: 10.1080/10543401003618066.
6
Multiple-arm superiority and non-inferiority designs with various endpoints.具有多种终点的多臂优效性和非劣效性设计。
Pharm Stat. 2007 Jan-Mar;6(1):43-52. doi: 10.1002/pst.242.
7
Sample size re-estimation for survival data in clinical trials with an adaptive design.具有适应性设计的临床试验中生存数据的样本量重新估计。
Pharm Stat. 2011 Jul-Aug;10(4):325-31. doi: 10.1002/pst.469. Epub 2010 Oct 28.
8
Design and analysis of non-inferiority mortality trials in oncology.肿瘤学中非劣效性死亡率试验的设计与分析
Stat Med. 2004 Sep 15;23(17):2771-4; author reply 2774-8. doi: 10.1002/sim.1897.
9
Approximate sample sizes for testing hypotheses about the ratio and difference of two means.用于检验关于两个均值的比率和差异的假设的近似样本量。
J Biopharm Stat. 1999 Nov;9(4):641-50. doi: 10.1081/bip-100101200.
10
Non-parametric assessment of non-inferiority with censored data.带有删失数据的非劣效性的非参数评估
Stat Med. 2006 Apr 15;25(7):1201-17. doi: 10.1002/sim.2444.

引用本文的文献

1
Sex Differences in Parkinson's Disease: A Narrative Review.帕金森病中的性别差异:一项叙述性综述。
Neurol Ther. 2025 Feb;14(1):57-70. doi: 10.1007/s40120-024-00687-6. Epub 2024 Dec 4.
2
The effects of safinamide according to gender in Chinese parkinsonian patients.中国帕金森病患者中依维莫司的性别效应。
Sci Rep. 2023 Nov 23;13(1):20632. doi: 10.1038/s41598-023-48067-8.
3
The Use of Covariates and Random Effects in Evaluating Predictive Biomarkers Under a Potential Outcome Framework.在潜在结果框架下评估预测性生物标志物时协变量和随机效应的使用
Ann Appl Stat. 2014 Dec;8(4):2336-2355. doi: 10.1214/14-AOAS773. Epub 2014 Dec 19.
4
Assessing the heterogeneity of treatment effects via potential outcomes of individual patients.通过个体患者的潜在结果评估治疗效果的异质性。
J R Stat Soc Ser C Appl Stat. 2013 Nov;62(5):687-704. doi: 10.1111/rssc.12012.
5
Testing for efficacy in adaptive clinical trials with enrichment.在具有富集作用的适应性临床试验中进行疗效测试。
Stat Med. 2014 Jul 20;33(16):2736-45. doi: 10.1002/sim.6127. Epub 2014 Feb 27.
6
Confidence intervals for the selected population in randomized trials that adapt the population enrolled.在调整入组人群的随机试验中,针对选定人群的置信区间。
Biom J. 2013 May;55(3):322-40. doi: 10.1002/bimj.201200080. Epub 2013 Apr 3.
7
Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment.优化随机试验设计以区分哪些亚群从治疗中获益。
Biometrika. 2011 Dec;98(4):845-860. doi: 10.1093/biomet/asr055.
8
Reporting of gender-related information in clinical trials of drug therapy for myocardial infarction.心肌梗死药物治疗临床试验中性别相关信息的报告
CMAJ. 1998 Aug 25;159(4):321-7.